This is the published version of the abstract:


Available from Deakin Research Online:

http://hdl.handle.net/10536/DRO/DU:30063525

Every reasonable effort has been made to ensure that permission has been obtained for items included in Deakin Research Online. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au

Copyright: 2013, Korean Society for Microbiology Biotechnology
Antifungal Synergy of Theaflavin and Epicatechin Combinations Against Candida albicans

Jonathan W. Betts1*, David W. Wareham1, Stephen J. Haswell2, and Stephen M. Kelly2

1Antimicrobial Research Group, Centre for Immunology and Infectious Disease, Blizard Institute, Queen Mary, University of London, London, E1 2AT, UK
2Department of Chemistry, University of Hull, Hull, HU6 7RX, UK

Introduction

C. albicans is a common opportunistic pathogen, often part of the human microflora, causing minor infections, such as mucosal candidiasis, in healthy individuals [17] but also life-threatening infections in the immunocompromised (HIV, cancer) and critically ill [16]. Although effective antifungal treatments are available (poreynes, azoles, echinocadins), there are increasing reports of resistance in Candida species [5, 19] and an on-going need to develop new antifungal agents. Plant polyphenolic compounds extracted from tea leaves (Camellia sinensis) have been shown to exhibit a variety of natural health benefits in humans [9] and also to have antimicrobial properties. Epicatechin (EP) and theaflavin (TF) derivatives have been shown to have potentially useful antibacterial activity against gram-positive and gram-negative bacteria [6, 20] as well as yeasts and molds [14, 18]. Tea polyphenols have also been shown to influence biofilm formation by C. albicans [4]. Enhanced activity, when polyphenols are tested either in combination or in the presence of other antimicrobials, has also been observed, and they may even suppress the emergence of resistance to existing antifungal drugs [3, 13]. In earlier studies, we identified synergy between theaflavin and epicatechin against both isolates of C. albicans was confirmed. Theaflavin:epicatechin combinations show real potential for future use as a treatment for infections caused by C. albicans.

Keywords: Antifungal, theaflavin, epicatechin, synergy, Candida albicans
purity) was purchased from Sigma-Aldrich, UK. All media, agar, and blank susceptibility discs were autoclaved prior to their use.

**Broth Microtiter Dilution Assays**

A 4.10 mg/ml TF stock solution was prepared by dissolving 81.92 mg of theaflavin in 0.50 ml of dimethylsulfoxide (DMSO) before the addition of 19.50 ml of sterile ISO-sensitest broth. From this stock solution, a double dilution was performed eight times into ISO-sensitest broth to give solutions of TF with nine different concentrations (4.1–0.064 mg/ml). A 2.05 mg/ml EC stock solution was prepared by dissolving 40.96 mg of EC in 0.5 ml of DMSO before the addition of 19.50 ml of sterile ISO-sensitest broth. From this stock solution, a double dilution was performed five times into ISO-sensitest broth to give solutions of EC with six different concentrations (2.05–0.064 mg/ml). A fixed volume (50 µl) of TF and EC was pipetted into each well of a microtiter plate, whereby each row and column contained a fixed amount of one antimicrobial agent and increasing concentrations of the other antimicrobial agent, providing final well concentrations (including inoculum) of 4–1,024 µg/ml of TF and 16–512 µg/ml of EC. Control wells contained either 2.5% DMSO alone, or TF alone (4–1,024 µg/ml). Epicatechin alone (16–512 µg/ml) was also tested. A 100 µl volume of a 5 x 10^6 colony forming unit (CFU)/ml suspension in ISO-sensitest broth was pipetted in order to inoculate each well with *C. albicans* NCTC 3255. This procedure was replicated for *C. albicans* NCTC 3179. All microtiter plates were incubated at 37°C for 24 h. A 3-fold replication of all experimental plates was undertaken, allowing the results to be provided as mean values.

Each well was observed for turbidity at the end of the incubation period. The lowest concentration at which no turbidity could be observed was taken as the MIC. Fractional inhibitory concentration indexes (FICIs) were determined based on the method previously described [7], whereby the FICa = MIC of compound a + compound b/MIC of compound a, the FICb = MIC of compound b + compound a/MIC of compound b, and the FICIs = FICA + FICb. Where a FICI value was calculated to be ≤0.5, synergy was recorded. A value >0.5–4.0 was noted as an additive effect and a value >4 was considered an antagonism effect between theaflavin and epicatechin.

The MIC of epicatechin alone was also determined by mictotiter dilution using wells containing 512–2,048 µg/ml for each of the *C. albicans* isolates. All microtiter plates were performed in triplicate and incubated at 37°C for 24 h.

**Disc Diffusion Assay**

A TF stock solution was prepared by adding 0.50 g of theaflavin powder to 5 ml of ethanol and stirring the resultant suspension for 10 min to provide a 100 mg/ml solution. A 100 mg/ml stock solution of epicatechin was prepared by gradually adding 0.05 g of epicatechin powder to 5 ml of ethanol and stirring the resultant suspension for 15–20 min until the polyphenolic compound had dissolved. A combined solution of theaflavin and epicatechin (2:1) was prepared by adding 0.50 g of theaflavin and 0.25 g of epicatechin to 5 ml of ethanol and stirring until both compounds had dissolved (15–20 min).

Polyphenol-susceptibility discs were prepared by pipetting 10 ml volumes of the individual polyphenol solutions directly onto blank discs. These were then dried for 20 min prior to the addition of any further solutions, if required. Single and combined discs (TF/EC) containing 2, 4, 6, and 8 mg of polyphenol were made by pipetting the appropriate volume of stock solution directly onto blank discs. Ethanol control discs were prepared using identical volumes of ethanol. All discs were then allowed to dry in a sterile Petri dish at room temperature, before their use, in order to completely remove all traces of solvent and thus eliminate any ethanol-mediated antifungal activity.

ISO-sensitive agar plates were independently inoculated with 5 x 10^5 CFU/ml solutions of *C. albicans* [15] using the standardization method [12]. Plate 1 comprised discs containing 2, 4, 6, or 8 mg of epicatechin and an ethanol control disc. Plate 2 comprised discs with 2, 4, 6, or 8 mg of theaflavin and an ethanol control disc and separate discs containing 2, 4, 6, or 8 mg of the 2:1 theaflavin: epicatechin combination. All experimental plates were incubated at 37°C for 24 h, after which the zones of inhibition were recorded (mm). Six-fold replication of all experimental plates was performed and the results were provided as mean values ± SE. Disc diffusion assays were also repeated after stock solutions had been stored for 7 days at 4°C to assess whether the stability of the compounds might affect the reproducibility of tests conducted using stored discs.

**Results and Discussion**

Epicatechin alone had little activity against *C. albicans* NCTC 3255 or NCTC 3179 (>2,048 µg/ml), but both strains were inhibited by theaflavin (1,024 µg/ml) (Table 1). This confirms previous findings that theaflavin alone has antifungal activity but with much lower MIC values than those previously reported [18]. Analysis of the results from the tests using 2:1 combinations of theaflavin and epicatechin revealed an even greater antifungal effect than that observed using solutions containing theaflavin alone, with MICs of

<table>
<thead>
<tr>
<th>C. albicans isolate number</th>
<th>Minimum inhibitory concentration (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TF</td>
</tr>
<tr>
<td>NCTC 3255</td>
<td>1,024 (0)</td>
</tr>
<tr>
<td>NCTC 3179</td>
<td>1,024 (0)</td>
</tr>
</tbody>
</table>

MIC = minimum inhibitory concentration, FICIs = fractional inhibitory concentration indexes, TF = theaflavin, EC = epicatechin.
256 and 128 µg/ml for *C. albicans* isolates NCTC 3255 and 3179, respectively. The noticeable and significant increase in antifungal activity suggests that synergy exists between the two polyphenols, confirmed by the FICIs of <0.5 (Table 1).

In the disc diffusion assays, zones of inhibition ranged from 10.2 mm (± 0.41) at 2 mg/disc to 14.5 mm (± 0.54) at 8 mg/disc against isolate NCTC 3255, and between 7.3 mm (± 0.52) at 2 mg/disc and 12.6 mm (± 0.52) at 8 mg/disc against isolate NCTC 3179. A significant difference in activity was observed in assays using theaflavin and epicatechin (2:1) in combination (Fig. 1). Combinations of theaflavin and epicatechin (2:1) tested against *C. albicans* isolate NCTC 3255 produced zones of inhibition ranging between 13.6 mm (± 0.52) at 2 mg/disc and 22.8 mm (± 0.75) at 8 mg/disc. Zones of inhibition produced by (2:1) combinations of theaflavin:epicatechin against isolate NCTC 3179 range between 7.3 mm (± 0.42) at 2 mg/disc and 19.2 mm at 8 mg/disc.

Disc diffusion assays conducted with stock solutions stored for 7 days at 4°C showed noticeable differences compared with those performed with stock solutions used immediately after preparation (Fig. 2). After 7 days, epicatechin remained inactive against both strains of *C. albicans*, but the antifungal action of theaflavin was also seen to be reduced. Discs containing 8 mg of TF generated mean zones of inhibition of 10.7 mm (± 0.41) and 10.1 mm (± 0.20) for isolates NCTC 3255 and NCTC 3179, respectively, equivalent to a 26% and 20% reduction in activity, respectively. This could result from oxidation of the theaflavin, reducing the amount of the biologically active polyphenol in the formulation. Stored discs containing the theaflavin:epicatechin (2:1) combinations also showed reduced antifungal activity but to a much lesser extent, with a 7% and 7.1% reduction in activity, respectively. The reason behind the lower reduction in activity could be a protective effect of theaflavin by epicatechin, with epicatechin acting as an antioxidant and...
reducing the rate at which theaflavin is oxidized, thus preserving a greater concentration of “active” theaflavin. This interpretation would be compatible with the results from a previous work, where the antioxidant ascorbic acid was found to prolong the activity lifespan of the polyphenol epigallocatechin gallate [8]. Further studies using HPLC analysis should be undertaken to calculate optimum storage times for theaflavin:epicatechin solutions. With the addition of another antioxidant, such as ascorbic acid, the shelf life of theaflavin and theaflavin:epicatechin combinations might be further increased.

Although the mechanisms responsible for polyphenol synergy are not fully understood, possible explanations include protection of theaflavin by epicatechin, similar to previous observations [8] in which ascorbic acid was shown to enhance the antibacterial activity of epigallocatechin gallate. Although the mechanism for the antimicrobial activity of polyphenols is unknown, previous studies have shown that theaflavins and catechins cause extensive damage to the cell wall of C. albicans [18]. The addition of epicatechin to theaflavin might intensify this pro-oxidant effect by further weakening the cell wall prior to any interaction with theaflavin, thereby reducing the concentration of theaflavin required for antifungal activity.

In conclusion, the results of this preliminary study highlight the synergy between theaflavin and epicatechin, when used against C. albicans, which could be harnessed to improve their antifungal activity. Any potential use of theaflavin:epicatechin combinations as a systemic treatment will need further investigation, given the relatively high MICs observed in vitro and the poor bioavailability of polyphenols [11]. However, a topical preparation could be useful as a treatment for skin or mucosal C. albicans infections, capitalizing on both the antifungal and antioxidant properties [10], which may be advantageous in promoting wound healing. Future research should look into the mechanisms behind the intrinsic, synergistic antimicrobial and antioxidant properties of these natural compounds.

Acknowledgments

We would like to gratefully acknowledge Unilever, Shanghai for their donation of theaflavin samples.

References